Medicine and Dentistry
Chronic Obstructive Pulmonary Disease
100%
COVID-19
32%
Placebo
28%
Lung
27%
Eosinophil
24%
Dupilumab
23%
Budesonide
16%
Cardiovascular Disease
15%
Asthma
15%
Disease Exacerbation
14%
Respiratory Monitoring
13%
Randomized Controlled Trial
12%
Severe Acute Respiratory Syndrome Coronavirus 2
11%
Primary Health Care
11%
Quality of Life
10%
Coughing
10%
Infection
9%
Cardiovascular System
9%
Prednisolone
8%
Diseases
8%
Nose Mucosa
7%
Mediator
7%
Breathing
7%
Magnetic Resonance Imaging
7%
Functional Magnetic Resonance Imaging
7%
Gestational Age
7%
Fluvoxamine
7%
Benralizumab
7%
Cardiovascular Risk
7%
Systematic Review
7%
Post-Hoc Analysis
7%
Clinician
7%
Adverse Event
7%
Lung Volume
6%
Dyspnea
6%
Adverse Outcome
5%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Obstructive Lung Disease
91%
Placebo
34%
Inflammation
26%
Dupilumab
23%
Diseases
16%
Cardiovascular Disease
15%
Asthma
14%
Budesonide
13%
Disease Exacerbation
12%
Randomized Controlled Trial
12%
Deterioration
9%
Coughing
9%
Adverse Event
8%
Coronavirinae
7%
Premature Labor
7%
Cardiovascular Risk
7%
Fluvoxamine
7%
SARS Coronavirus
7%
Adverse Outcome
7%
Prednisolone
7%
Infection
6%
Clinical Trial
5%
Bronchodilating Agent
5%
Dyspnea
5%
Nursing and Health Professions
Obstructive Lung Disease
23%
Budesonide
11%
Fluvoxamine
7%
Gold Standard
7%
Diseases
7%
Placebo
6%
Disease Exacerbation
6%
Respiratory Monitoring
5%
Multichannel Recorder
5%